This Article Full Text Full Text (PDF) An erratum has been published Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalpoe, J. S. Articles by Claas, E. C. J. Search for Related Content PubMed PubMed Citation Articles by Kalpoe, J. S. Articles by Claas, E. C. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2004, p. 1498-1504, Vol. 42, No. 4
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.4.1498-1504.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Validation of Clinical Application of Cytomegalovirus Plasma DNA Load Measurement and Definition of Treatment Criteria by Analysis of Correlation to Antigen Detection

Department of Medical Microbiology, Leiden University Medical Center, Leiden,¹ Section of Clinical Virology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands²

Received 11 April 2003/ Returned for modification 11 August 2003/ Accepted 25 November 2003

Successful preemptive cytomegalovirus (CMV) therapy in transplant patients depends on the availability of sensitive, specific, and timely diagnostic tests for CMV infections. The pp65 antigenemia assay has been used for this purpose with considerable success. Quantification of CMV DNA is currently regarded to be an alternative diagnostic approach. The precise relationship between these two methods has still to be defined, but is essential to compare diagnostic results. This study compared the results of both assays with a large series of transplant recipients in different categories. An internally controlled quantitative real-time CMV DNA PCR was used to test 409 plasma samples from solid organ transplant (SOT) and stem cell transplant (SCT) patients. Levels of CMV DNA in plasma correlated well with classified outcomes of the pp65 antigenemia test. Despite this correlation, the quantitative CMV PCR values in a class of antigen test results were within a wide range, and the definition of an optimal cutoff value for initiating treatment required further analysis by a receiver-operating characteristic curve analysis. This is essential for reactivating infections in particular. For the SCT patients the optimal cutoff value of CMV DNA load defining relevant viral reactivation (in this assay, 10,000 copies/ml) was slightly higher than that for the SOT patients (6,300 copies/ml). Based on a comparison with the established pp65 antigenemia assay, quantification of CMV DNA in plasma appeared to be capable of guiding the clinical management of transplant recipients. This approach may have important advantages, which include a superior reproducibility and sensitivity, allowing the inclusion of kinetic criteria in clinical guidelines.

This article has been cited by other articles:

• Gimeno, C., Solano, C., Latorre, J. C., Hernandez-Boluda, J. C., Clari, M. A., Remigia, M. J., Furio, S., Calabuig, M., Tormo, N., Navarro, D. (2008). Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant Recipients. J. Clin. Microbiol. 46: 3311-3318 [Abstract] [Full Text]  
• Kalpoe, J S, Douwes Dekker, P B, van Krieken, J H J M, Baatenburg de Jong, R J, Kroes, A C M (2006). Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area. J. Clin. Pathol. 59: 537-541 [Abstract] [Full Text]  
• Huurman, V. A.L., Kalpoe, J. S., van de Linde, P., Vaessen, N., Ringers, J., Kroes, A. C.M., Roep, B. O., De Fijter, J. W. (2006). Choice of Antibody Immunotherapy Influences Cytomegalovirus Viremia in Simultaneous Pancreas-Kidney Transplant Recipients. Diabetes Care 29: 842-847 [Abstract] [Full Text]  
• Espy, M. J., Uhl, J. R., Sloan, L. M., Buckwalter, S. P., Jones, M. F., Vetter, E. A., Yao, J. D. C., Wengenack, N. L., Rosenblatt, J. E., Cockerill, F. R. III, Smith, T. F. (2006). Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing. Clin. Microbiol. Rev. 19: 165-256 [Abstract] [Full Text]  
• Schuurman, T., van Breda, A., de Boer, R., Kooistra-Smid, M., Beld, M., Savelkoul, P., Boom, R. (2005). Reduced PCR Sensitivity Due to Impaired DNA Recovery with the MagNA Pure LC Total Nucleic Acid Isolation Kit. J. Clin. Microbiol. 43: 4616-4622 [Abstract] [Full Text]